These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 371813)
1. In vivo effects of 5-fluorouracil and ftorafur[1-(tetrahydrofuran-2-yl)-5-fluorouracil] on murine mammary tumors and small intestine. Pallavicini MG; Cohen AM; Dethlefsen LA; Gray JW Cell Tissue Kinet; 1979 Mar; 12(2):177-89. PubMed ID: 371813 [TBL] [Abstract][Full Text] [Related]
2. Comparing cell kinetic studies of the effect of ftorafur and 5-fluorouracil on the L 1210 ascites tumor. Schultze B; Jellinghaus W; Weis G; Müller V; Maurer W J Cancer Res Clin Oncol; 1981; 100(1):25-40. PubMed ID: 6787060 [TBL] [Abstract][Full Text] [Related]
3. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil]. Shirasaka T; Shimamoto Y; Kato T; Fukushima M Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831 [TBL] [Abstract][Full Text] [Related]
4. Kinetic alterations induced by 5-fluorouracil in bone marrow, intestinal mucosa, and tumor. Myers CE; Young RC; Chabner BA Cancer Res; 1976 May; 36(5):1653-8. PubMed ID: 1268826 [TBL] [Abstract][Full Text] [Related]
5. Comparison of 5-fluorouracil and ftorafur. I. Quantitative and qualitative differences in toxicity to mice. Johnson RK; Garibjanian BT; Houchens DP; Kline I; Gaston MR; Syrkin AB; Goldin A Cancer Treat Rep; 1976 Sep; 60(9):1335-45. PubMed ID: 797449 [TBL] [Abstract][Full Text] [Related]
6. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors. Garibjanian BT; Johnson RK; Kline I; Vadlamudi S; Gang M; Venditti JM; Goldin A Cancer Treat Rep; 1976 Sep; 60(9):1347-61. PubMed ID: 797450 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the actions of 5-fluorouracil and ftorafur in Escherichia coli. Saunders PP; Chao LY Antimicrob Agents Chemother; 1977 Mar; 11(3):451-4. PubMed ID: 324392 [TBL] [Abstract][Full Text] [Related]
8. Enhanced accumulation of 5-fluorouracil in human tumors in athymic mice by co-administration of Ftorafur and uracil. Tang SG; Hornbeck CL; Byfield JE Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1687-9. PubMed ID: 6434499 [TBL] [Abstract][Full Text] [Related]
9. [Mechanism of the chromosome damaging effect of ftorafur]. Volgareva GM; Sokova OI; Pogosiants EE Genetika; 1977; 13(3):461-7. PubMed ID: 142687 [TBL] [Abstract][Full Text] [Related]
10. Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil. Kato T; Shimamoto Y; Uchida J; Ohshimo H; Abe M; Shirasaka T; Fukushima M Anticancer Res; 2001; 21(3B):1705-12. PubMed ID: 11497250 [TBL] [Abstract][Full Text] [Related]
11. Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats. Yoshisue K; Hironaga K; Yamaguchi S; Yamamoto A; Nagayama S; Kawaguchi Y Cancer Chemother Pharmacol; 2000; 46(1):51-6. PubMed ID: 10912578 [TBL] [Abstract][Full Text] [Related]
12. [Studies on the mechanism of antitumor activity of 5-FU and its derivatives--relationship between the inhibition of tumor growth and the inhibition of thymidylate synthetase in vivo]. Nakamura H; Yu-Qin W; Miyauchi S; Nishioka N; Tanaka H; Harada N; Shirasaka T; Fujii S Gan To Kagaku Ryoho; 1984 May; 11(5):1049-55. PubMed ID: 6426401 [TBL] [Abstract][Full Text] [Related]
13. Differential effects of 5-fluorouracil analogs on humoral and cell-mediated responses in mice: augmentation of delayed hypersensitivity response against picryl chloride by 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione (FD-1), a new anti-tumor drug. Yamada Y; Miyauchi S; Unemi N J Clin Lab Immunol; 1980 Nov; 4(3):153-7. PubMed ID: 6451710 [TBL] [Abstract][Full Text] [Related]
14. [Prevention of 5-FU induced toxicity in C3 H/HE mice with interferon or with interferon inducers (poly 1: C, OK-432, Lentinan)]. Akimoto M; Ueki H; Nakajima Y; Matano S; Ewasaki H; Abe R; Kasai M Gan To Kagaku Ryoho; 1984 Jul; 11(7):1462-7. PubMed ID: 6204597 [TBL] [Abstract][Full Text] [Related]
15. [Effect of cepharanthine on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207)--5-fluorouracil delivery into tumor tissue]. Ono M Nihon Gan Chiryo Gakkai Shi; 1989 Jul; 24(7):1379-92. PubMed ID: 2509603 [TBL] [Abstract][Full Text] [Related]
16. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil. Fukushima M; Shimamoto Y; Kato T; Uchida J; Yonekura R; Ohshimo H; Shirasaka T Anticancer Drugs; 1998 Oct; 9(9):817-23. PubMed ID: 9840729 [TBL] [Abstract][Full Text] [Related]
17. Hydroxylated metabolies of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (Ftorafur) in rats and rabbits. Wu AT; Au JL; Sadée W Cancer Res; 1978 Jan; 38(1):210-4. PubMed ID: 338145 [TBL] [Abstract][Full Text] [Related]
18. Comparative studies on the immunosuppressive effect among 5'-deoxy-5-fluorouridine, ftorafur, and 5-fluorouracil. Ohta Y; Sueki K; Kitta K; Takemoto K; Ishitsuka H; Yagi Y Gan; 1980 Apr; 71(2):190-6. PubMed ID: 6451468 [TBL] [Abstract][Full Text] [Related]
19. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Shirasaka T; Shimamato Y; Ohshimo H; Yamaguchi M; Kato T; Yonekura K; Fukushima M Anticancer Drugs; 1996 Jul; 7(5):548-57. PubMed ID: 8862723 [TBL] [Abstract][Full Text] [Related]
20. 5-Fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer. Cao S; Frank C; Shirasaka T; Rustum YM Clin Cancer Res; 1995 Aug; 1(8):839-45. PubMed ID: 9816053 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]